{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:34:29Z","timestamp":1782311669308,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T00:00:00Z","timestamp":1669420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T00:00:00Z","timestamp":1669420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["LGF22H060003"],"award-info":[{"award-number":["LGF22H060003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tetrandrine, a bisbenzylisoquinoline (BBI) alkaloid extracted from <jats:italic>Stephania tetrandra<\/jats:italic> (S. Moore), and is widely used in several diseases such as tuberculosis, hyperglycemia, malaria, and tumors. Tetrandrine was recently shown to prevent bone loss in ovariectomized mice. However, the specific mechanism underlying osteoclastogenesis inhibition remains unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Tetrandrine\u2019s cytotoxicity to cells was determined using the Cell Counting Kit-8 assay. Tartrate-resistant acid phosphatase staining, immunofluorescence and bone resorption assay were performed to evaluate osteoclasts\u2019 differentiation and absorption capacity. The bone-forming capacity was assessed using alkaline phosphatase and Alizarin red S staining. qPCR and Western blotting were applied to assess the related genes and protein expression. Tetrandrine\u2019s impact on TRAIL was demonstrated through a co-immunoprecipitation assay. Animal experiments were performed for the detection of the therapeutic effect of Tetrandrine on osteoporosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Tetrandrine attenuated RANKL-induced osteoclastogenesis and decreased the related gene expression. The co-immunoprecipitation assay revealed that Tetrandrine administration accelerated the ubiquitination of TNF-related apoptosis-inducing ligand (TRAIL), which was subsequently degraded. Moreover, TRAIL overexpression was found to partially reverse the Tetrandrine-induced inhibition of osteoclastogenesis. Meanwhile, Tetrandrine significantly inhibited the phosphorylation of p38, p65, JNK, IKB\u03b1 and IKK\u03b1\/\u03b2, while the TRAIL overexpression weakened this effect. In addition, Tetrandrine promoted osteogenesis and inhibited the TRAIL expression in osteoblasts. Tetrandrine consistently improved bone destruction by stimulating bone formation and inhibiting bone resorption in an OVX-induced mouse model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Tetrandrine inhibits RANKL-induced osteoclastogenesis by promoting TRAIL degradation and promotes osteoblast differentiation, suggesting its potential in antiosteopenia pharmacotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10020-022-00568-4","type":"journal-article","created":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T01:18:52Z","timestamp":1669511932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Tetrandrine inhibits RANKL-induced osteoclastogenesis by promoting the degradation of TRAIL"],"prefix":"10.1186","volume":"28","author":[{"given":"Jiarui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengji","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6000-7197","authenticated-orcid":false,"given":"Fengchao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,26]]},"reference":[{"key":"568_CR1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.intimp.2016.04.024","volume":"36","author":"J An","year":"2016","unstructured":"An J, Hao D, Zhang Q, Chen B, Zhang R, Wang Y, et al. Natural products for treatment of bone erosive diseases: the effects and mechanisms on inhibiting osteoclastogenesis and bone resorption. Int Immunopharmacol. 2016;36:118\u201331.","journal-title":"Int Immunopharmacol"},{"key":"568_CR2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.biopha.2017.10.116","volume":"97","author":"NC Bhagya","year":"2018","unstructured":"Bhagya NC, Chandrashekar KR. Tetrandrine and cancer\u2014an overview on the molecular approach. Biomed Pharmacother. 2018;97:624\u201332.","journal-title":"Biomed Pharmacother"},{"key":"568_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/scrt534","volume":"5","author":"JD Boerckel","year":"2014","unstructured":"Boerckel JD, Mason DE, McDermott AM, Alsberg E. Microcomputed tomography: approaches and applications in bioengineering. Stem Cell Res Ther. 2014;5:144.","journal-title":"Stem Cell Res Ther"},{"key":"568_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/jbmr.1885","volume":"28","author":"BF Boyce","year":"2013","unstructured":"Boyce BF. Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res. 2013;28:711\u201322.","journal-title":"J Bone Miner Res"},{"key":"568_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"W Boyle","year":"2003","unstructured":"Boyle W, Simonet W, Lacey DJN. Osteoclast differentiation and activation. Nature. 2003;423:337\u201342.","journal-title":"Nature"},{"key":"568_CR6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.tcb.2009.05.006","volume":"19","author":"A Chariot","year":"2009","unstructured":"Chariot A. The NF-kappaB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol. 2009;19:404\u201313.","journal-title":"Trends Cell Biol"},{"key":"568_CR7","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1080\/15476286.2019.1624470","volume":"16","author":"X Chen","year":"2019","unstructured":"Chen X, Ouyang Z, Shen Y, Liu B, Zhang Q, Wan L, et al. CircRNA_28313\/miR-195a\/CSF1 axis modulates osteoclast differentiation to affect OVX-induced bone absorption in mice. RNA Biol. 2019;16:1249\u201362.","journal-title":"RNA Biol"},{"key":"568_CR8","doi-asserted-by":"publisher","first-page":"16069","DOI":"10.1038\/nrdp.2016.69","volume":"2","author":"R Eastell","year":"2016","unstructured":"Eastell R, O\u2019Neill TW, Hofbauer LC, Langdahl B, Reid IR, Gold DT, et al. Postmenopausal osteoporosis. Nat Rev Dis Primers. 2016;2:16069.","journal-title":"Nat Rev Dis Primers"},{"key":"568_CR9","doi-asserted-by":"publisher","first-page":"14363","DOI":"10.1074\/jbc.273.23.14363","volume":"273","author":"J Emery","year":"1998","unstructured":"Emery J, McDonnell P, Burke M, Deen K, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor f or the cytotoxic ligand TRAIL. J Biol Chem. 1998;273:14363\u20137.","journal-title":"J Biol Chem"},{"key":"568_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41413-020-00120-2","volume":"9","author":"T Fujii","year":"2021","unstructured":"Fujii T, Murata K, Mun S, Bae S, Lee Y, Pannellini T, et al. MEF2C regulates osteoclastogenesis and pathologic bone resorption via c-FOS. Bone Res. 2021;9:4.","journal-title":"Bone Res"},{"key":"568_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canlet.2017.08.036","volume":"409","author":"Z Gamie","year":"2017","unstructured":"Gamie Z, Kapriniotis K, Papanikolaou D, Haagensen E, Da Conceicao Ribeiro R, Dalgarno K, et al. TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: pre-clinical and clinical data. Cancer Lett. 2017;409:66\u201380.","journal-title":"Cancer Lett"},{"key":"568_CR12","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/jor.23155","volume":"34","author":"L Gao","year":"2016","unstructured":"Gao L, Feng Q, Zhang X, Wang Q, Cui YJ. Tetrandrine suppresses articular inflammatory response by inhibiting pro-inflammatory factors via NF-\u03baB inactivation. J Orthop Res. 2016;34:1557\u201368.","journal-title":"J Orthop Res"},{"key":"568_CR13","doi-asserted-by":"publisher","first-page":"710169","DOI":"10.3389\/fphar.2021.710169","volume":"12","author":"X Gao","year":"2021","unstructured":"Gao X, Wu Q, Zhang X, Tian J, Liang D, Min Y, et al. Salvianolate ameliorates osteopenia and improves bone quality in prednisone-treated rheumatoid arthritis rats by regulating RANKL\/RANK\/OPG signaling. Front Pharmacol. 2021;12:710169.","journal-title":"Front Pharmacol"},{"key":"568_CR14","doi-asserted-by":"publisher","first-page":"BSR20190432","DOI":"10.1042\/BSR20190432","volume":"39","author":"T Guo","year":"2019","unstructured":"Guo T, Xing Y, Zhu H, Yang L, Liu G, Qiao XJ. Extracellular regulated kinase 5 mediates osteoporosis through modulating viability and apoptosis of osteoblasts in ovariectomized rats. Biosci Rep. 2019;39:BSR20190432.","journal-title":"Biosci Rep"},{"key":"568_CR15","doi-asserted-by":"publisher","first-page":"C1397","DOI":"10.1152\/ajpcell.00311.2009","volume":"297","author":"N Henney","year":"2009","unstructured":"Henney N, Li B, Elford C, Reviriego P, Campbell A, Wann K, et al. A large-conductance (BK) potassium channel subtype affects both growth and mineralization of human osteoblasts. Am J Physiol Cell Physiol. 2009;297:C1397\u2013408.","journal-title":"Am J Physiol Cell Physiol"},{"key":"568_CR16","doi-asserted-by":"publisher","first-page":"684007","DOI":"10.3389\/fcell.2021.684007","volume":"9","author":"C Jiang","year":"2021","unstructured":"Jiang C, Ma Q, Wang S, Shen Y, Qin A, Fan S, et al. Oxymatrine attenuates osteoclastogenesis via modulation of ROS-mediated SREBP2 signaling and counteracts ovariectomy-induced osteoporosis. Front Cell Dev Biol. 2021;9:684007.","journal-title":"Front Cell Dev Biol"},{"key":"568_CR17","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/jbmr.242","volume":"26","author":"C Li","year":"2011","unstructured":"Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, et al. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-\u03baB and MAPK signaling pathways. J Bone Miner Res. 2011;26:644\u201356.","journal-title":"J Bone Miner Res"},{"key":"568_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cytogfr.2020.02.003","volume":"52","author":"J Li","year":"2020","unstructured":"Li J, Chen X, Lu L, Yu XJ. The relationship between bone marrow adipose tissue and bone metabolism in postmenopausal osteoporosis. Cytokine Growth Factor Rev. 2020;52:88\u201398.","journal-title":"Cytokine Growth Factor Rev"},{"key":"568_CR19","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10565-020-09578-6","volume":"37","author":"X Li","year":"2021","unstructured":"Li X, Wang Y, Li L, Zhou S, Zhao FJ. Sclareol inhibits RANKL-induced osteoclastogenesis and promotes osteoblastogenesis through promoting CCN1 expression via repressing the MAPK pathway. Cell Biol Toxicol. 2021;37:849\u201371.","journal-title":"Cell Biol Toxicol"},{"key":"568_CR20","doi-asserted-by":"publisher","first-page":"40800","DOI":"10.18632\/oncotarget.8315","volume":"7","author":"T Liu","year":"2016","unstructured":"Liu T, Liu X, Li W. Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy. Oncotarget. 2016;7:40800\u201315.","journal-title":"Oncotarget"},{"key":"568_CR21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s13018-021-02678-x","volume":"16","author":"F Migliorini","year":"2021","unstructured":"Migliorini F, Maffulli N, Colarossi G, Eschweiler J, Tingart M, Betsch M, et al. Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis. J Orthop Surg Res. 2021;16:533.","journal-title":"J Orthop Surg Res"},{"key":"568_CR22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2147\/PPA.S46192","volume":"8","author":"T Miyazaki","year":"2014","unstructured":"Miyazaki T, Tokimura F, Tanaka S. A review of denosumab for the treatment of osteoporosis. Patient Prefer Adherence. 2014;8:463\u201371.","journal-title":"Patient Prefer Adherence"},{"key":"568_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1600-065X.2009.00821.x","volume":"231","author":"T Negishi-Koga","year":"2009","unstructured":"Negishi-Koga T, Takayanagi H. Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol Rev. 2009;231:241\u201356.","journal-title":"Immunol Rev"},{"key":"568_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejca.2017.01.028","volume":"76","author":"E Palmerini","year":"2017","unstructured":"Palmerini E, Chawla N, Ferrari S, Sudan M, Picci P, Marchesi E, et al. Denosumab in advanced\/unresectable giant-cell tumour of bone (GCTB): for how long? Eur J Cancer. 2017;76:118\u201324.","journal-title":"Eur J Cancer"},{"key":"568_CR25","doi-asserted-by":"publisher","first-page":"4718","DOI":"10.1002\/adma.201301385","volume":"25","author":"L Pan","year":"2013","unstructured":"Pan L, Wang H, Xie Z, Li Z, Tang X, Xu Y, et al. Novel conjugation of tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) with monomethyl auristatin E for efficient antitumor drug delivery. Adv Mater. 2013;25:4718\u201322.","journal-title":"Adv Mater"},{"key":"568_CR26","doi-asserted-by":"publisher","first-page":"25103","DOI":"10.1074\/jbc.R109.041087","volume":"285","author":"L Raggatt","year":"2010","unstructured":"Raggatt L, Partridge N. Cellular and molecular mechanisms of bone remodeling. J Biol Chem. 2010;285:25103\u20138.","journal-title":"J Biol Chem"},{"key":"568_CR27","doi-asserted-by":"publisher","first-page":"25143","DOI":"10.1038\/srep25143","volume":"6","author":"Y Sambandam","year":"2016","unstructured":"Sambandam Y, Baird K, Stroebel M, Kowal E, Balasubramanian S, Reddy S. Microgravity induction of TRAIL expression in preosteoclast cells enhances osteoclast differentiation. Sci Rep. 2016;6:25143.","journal-title":"Sci Rep"},{"key":"568_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/08820139.2020.1837864","volume":"51","author":"F Shi","year":"2022","unstructured":"Shi F, Ni L, Gao Y. Tetrandrine attenuates cartilage degeneration, osteoclast proliferation, and macrophage transformation through inhibiting P65 phosphorylation in ovariectomy-induced osteoporosis. Immunol Investig. 2022;51:465\u201379.","journal-title":"Immunol Investig"},{"key":"568_CR29","first-page":"484","volume":"17","author":"H Takayanagi","year":"2007","unstructured":"Takayanagi H. Osteoclast differentiation and activation. Clin Calcium. 2007;17:484\u201392.","journal-title":"Clin Calcium"},{"key":"568_CR30","first-page":"345","volume":"5","author":"A Trouvin","year":"2010","unstructured":"Trouvin A, Go\u00ebb V. Receptor activator of nuclear factor-\u03baB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging. 2010;5:345\u201354.","journal-title":"Clin Interv Aging"},{"key":"568_CR31","doi-asserted-by":"publisher","first-page":"e59171","DOI":"10.1371\/journal.pone.0059171","volume":"8","author":"Z Wei","year":"2013","unstructured":"Wei Z, Tong B, Xia Y, Lu Q, Chou G, Wang Z, et al. Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs\/NF-\u03baB\/c-Fos\/NFATc1 pathways. PLoS ONE. 2013;8:e59171.","journal-title":"PLoS ONE"},{"key":"568_CR32","doi-asserted-by":"publisher","first-page":"107659","DOI":"10.1016\/j.pharmthera.2020.107659","volume":"217","author":"W Xu","year":"2021","unstructured":"Xu W, Chen S, Wang X, Tanaka S, Onda K, Sugiyama K, et al. Molecular mechanisms and therapeutic implications of tetrandrine and cepharanthine in T cell acute lymphoblastic leukemia and autoimmune diseases. Pharmacol Ther. 2021;217:107659.","journal-title":"Pharmacol Ther"},{"key":"568_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41413-020-00106-0","volume":"8","author":"Y Yahiro","year":"2020","unstructured":"Yahiro Y, Maeda S, Morikawa M, Koinuma D, Jokoji G, Ijuin T, et al. BMP-induced Atoh8 attenuates osteoclastogenesis by suppressing Runx2 transcriptional activity and reducing the Rankl\/Opg expression ratio in osteoblasts. Bone Res. 2020;8:32.","journal-title":"Bone Res"},{"key":"568_CR34","doi-asserted-by":"publisher","first-page":"18245","DOI":"10.1074\/jbc.M610701200","volume":"282","author":"T Yamashita","year":"2007","unstructured":"Yamashita T, Yao Z, Li F, Zhang Q, Badell I, Schwarz E, et al. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem. 2007;282:18245\u201353.","journal-title":"J Biol Chem"},{"key":"568_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41413-021-00151-3","volume":"9","author":"W Yang","year":"2021","unstructured":"Yang W, Lu X, Zhang T, Han W, Li J, He W, et al. TAZ inhibits osteoclastogenesis by attenuating TAK1\/NF-\u03baB signaling. Bone Res. 2021;9:33.","journal-title":"Bone Res"},{"key":"568_CR36","doi-asserted-by":"publisher","first-page":"e38048","DOI":"10.1371\/journal.pone.0038048","volume":"7","author":"M Yen","year":"2012","unstructured":"Yen M, Hsu P, Liao H, Lee B, Tsai H. TRAF-6 dependent signaling pathway is essential for TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation. PLoS ONE. 2012;7:e38048.","journal-title":"PLoS ONE"},{"key":"568_CR37","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s13238-013-3003-3","volume":"4","author":"W Zeng","year":"2013","unstructured":"Zeng W, Yan Y, Zhang F, Zhang C, Liang W. Chrysin promotes osteogenic differentiation via ERK\/MAPK activation. Protein Cell. 2013;4:539\u201347.","journal-title":"Protein Cell"},{"key":"568_CR38","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.3389\/fphar.2019.01530","volume":"10","author":"Z Zhong","year":"2019","unstructured":"Zhong Z, Qian Z, Zhang X, Chen F, Ni S, Kang Z, et al. Tetrandrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis. Front Pharmacol. 2019;10:1530.","journal-title":"Front Pharmacol"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-022-00568-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-022-00568-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-022-00568-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T01:29:11Z","timestamp":1669512551000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1186\/s10020-022-00568-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,26]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["568"],"URL":"https:\/\/doi.org\/10.1186\/s10020-022-00568-4","relation":{},"ISSN":["1076-1551","1528-3658"],"issn-type":[{"value":"1076-1551","type":"print"},{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,26]]},"assertion":[{"value":"8 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies were carried out in conformity to the National Institutes of Health (NIH) guidelines and protocols for laboratory animal use and care. The study was subject to approval by the ethics committee of the First Affiliated Hospital College of Medicine, Zhejiang University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}